Most explanations of FDA device classification stop at the regulatory textbook version: Class I is low risk, Class II is moderate risk, Class III is high risk, and here’s a chart. That’s accurate, but it skips the question that actually matters to an OEM sourcing components: does it change who you should be buying tubing and catheter parts from?
It does. The classification your device carries determines the level of documentation, traceability, and process control your extrusion partner needs to support, long before your device ever reaches a review board. Here’s what separates Class II from Class III, where catheters actually fall, and what to ask your component supplier once you know.
What Class I, II, and III Actually Mean
The FDA maintains classifications for roughly 1,700 generic device types, organized across 16 medical specialty panels. The device-count split often cited for these three classes (roughly 47% Class I, 43% Class II, 10% Class III) traces back to FDA’s own device database. Every device falls into one of three tiers based on two factors: its intended use and the risk it poses to the patient.
- Class I devices carry the lowest risk and are regulated under general controls, the baseline manufacturing and labeling requirements that apply to every device, regardless of class. Tongue depressors and elastic bandages are typical examples.
- Class II devices carry moderate risk. General controls aren’t considered sufficient on their own, so the FDA adds special controls: things like performance standards, specific labeling requirements, and postmarket surveillance. Most Class II devices clear the market through 510(k) premarket notification.
- Class III devices carry the highest risk, usually because they’re life-sustaining, life-supporting, or implanted. These require Premarket Approval (PMA), the most rigorous submission the FDA has, typically backed by clinical data.
510(k) vs. PMA: The Practical Difference
The distinction between these two pathways is where the real workload difference shows up. A 510(k) requires demonstrating that a new device is “substantially equivalent” to an existing, already-cleared device, a predicate device. It’s a comparison exercise, and for many Class II devices it can move relatively quickly.
A PMA doesn’t have that shortcut. It requires the manufacturer to independently prove safety and effectiveness, generally through clinical investigation, and the FDA’s review of the manufacturing process itself is considerably more invasive. That difference cascades downstream to every supplier involved in the build, including the one extruding the tubing.
Where Catheters Fall, And Why It’s Not Always Obvious
Catheters are one of the more common Class II examples, alongside blood pressure cuffs, syringes, and absorbable sutures. Most catheter-based delivery systems clear the market through 510(k).
But “catheter” isn’t a single regulatory category, and a meaningful subset of catheter-based devices are Class III: certain neurovascular catheters, structural heart delivery systems, and drug- or device-combination products among them. The classification depends on intended use and risk profile, not on the fact that the device happens to be catheter-shaped.
What Changes for OEMs When a Device Is Class III
The jump from Class II to Class III isn’t just more paperwork. It changes the standard of proof required at every step:
- Documentation depth. Class III programs typically demand full device history records and design history files with a level of granularity that Class II general/special controls don’t require.
- Traceability. Material lot traceability, often down to individual component batches, becomes a hard requirement rather than a best practice.
- Process validation rigor. Manufacturing processes need documented validation (installation, operational, and performance qualification) with less tolerance for deviation.
- Change control. Even minor changes to a validated process or material source may trigger a new round of regulatory review.
Miss any one of these on a Class III program, and the delay isn’t measured in days. It’s measured in review cycles.
What This Means When You’re Vetting an Extrusion Partner
If you’re sourcing tubing or catheter components for a Class III device, the questions worth asking a potential supplier go beyond price and lead time:
- Can they provide full material lot traceability, not just certificates of conformance?
- Is their quality system built to support device history record requirements, or only general controls-level documentation?
- Have they supported a PMA-track program before, and can they speak to what changed operationally when they did?
Getting this right at the sourcing stage, before tooling, before a single foot of tubing is extruded, is far cheaper than discovering a documentation gap mid-program. It’s also why material and regulatory strategy alignment tends to work best as an early conversation with your component supplier rather than a late-stage one.
The Bottom Line
Class II and Class III aren’t just labels on a regulatory form. They’re a proxy for how much rigor your entire supply chain needs to carry, starting with the partner making your tubing. Understanding where your device sits, and what that means for the suppliers you choose, is groundwork worth doing before development gets underway, not after a review cycle stalls out.
Related Reading: Process Validation in Medical Devices: IQ, OQ, and PQ Explained
